Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated NSCLC
Findings from the CHRYSALIS study in patients with non-small cell lung cancer after progression on platinum-based chemotherapy
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1651 results
First Direct Comparison of Ibrutinib versus Acalabrutinib in Patients with Previously Treated CLL
Phase III study results point to noninferiority of acalabrutinib, while it provides improved safety in patients with previously treated chronic lymphocytic leukaemia
FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer
KEYNOTE-522 study was the basis for approval in the neoadjuvant and adjuvant setting
No Link Between Viral Vector in Zynteglo and Acute Myeloid Leukaemia
Update of recommendations for monitoring patients
EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib
It is intended for the treatment of leukaemia and gastrointestinal stromal tumours
Findings from a Population-Based Study on Cancers Associated with Alcohol Consumption
Data from a study across the world point to a substantial number of cancer cases that could potentially be avoided
Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition Genes Continue to Be at Increased Risk of Breast Cancer
Women in this age category qualify for clinical genetic testing and magnetic resonance imaging screening
Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab
Withdrawal concerns the application to extend the use of atezolizumab to include the treatment of early or locally advanced triple-negative breast cancer
FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma
The approval concerns management of patients with no MSI-H/dMMR tumours
Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant Neurocognitive Decline
Findings from a prospective study from the St Jude Lifetime Cohort
Pembrolizumab Demonstrates Robust, Durable Antitumour Activity and Promising Survival in Advanced Cutaneous Squamous Cell Carcinoma
Results of the second interim analysis of the KEYNOTE-629 study
Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With Pembrolizumab
The results of a phase II study in patients with recurrent mismatch repair deficient and/or microsatellite instability-high endometrial cancer